SODIUM P.A.S. Drug Patent Profile
✉ Email this page to a colleague
When do Sodium P.a.s. patents expire, and what generic alternatives are available?
Sodium P.a.s. is a drug marketed by Lannett and is included in one NDA.
The generic ingredient in SODIUM P.A.S. is aminosalicylate sodium. There are three drug master file entries for this compound. Additional details are available on the aminosalicylate sodium profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SODIUM P.A.S.?
- What are the global sales for SODIUM P.A.S.?
- What is Average Wholesale Price for SODIUM P.A.S.?
Summary for SODIUM P.A.S.
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 92 |
| Clinical Trials: | 3,720 |
| Patent Applications: | 6 |
| DailyMed Link: | SODIUM P.A.S. at DailyMed |
Recent Clinical Trials for SODIUM P.A.S.
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Juvenile Diabetes Research Foundation | Phase 4 |
| King's College London | Phase 4 |
| Quince Therapeutics S.p.A. | Phase 3 |
US Patents and Regulatory Information for SODIUM P.A.S.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lannett | SODIUM P.A.S. | aminosalicylate sodium | TABLET;ORAL | 080138-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
